18 F]2-fluoro-2-deoxy-glucose (FDG-PET) in patients with Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) scheduled for high-dose therapy with stem cell transplantation (HDT/SCT). Inclusion criteria were the presence of an FDG-PET scan after chemotherapy (ChT) within 8 weeks prior to HDT/SCT and available follow-up data. Sixteen patients (10 NHL and six HD) were observed during a follow-up period of 4 to 28 months (median 13 months). Before SCT, five patients had a negative PET, three were weakly positive, two moderately positive, and six strongly positive. None of the five patients with a negative PET before HDT/SCT relapsed and two of three patients with a weakly positive scan are still in remission after HDT/SCT. Of eight patients with a moderate or high positive PET before HDT/SCT, seven relapsed and one died of early HDT/SCT related complications (P Ͻ 0.01). Three of eight relapsing patients died of lymphoma 5 to 10 months after SCT and in one additional patient not responding to HDT/SCT, the main cause of death was chronic toxicity 4 months after transplantation. After 12 months, in PET-negative patients the overall and relapse-free survival was 100%, in PET-positive patients 55% and 18%, respectively. In NHL, two patients with negative PET, but with an age-adjusted international prognostic index (AaIPI) of 2 and one with AaIPI ‫؍‬ 1 are still in remission. In the seven PET-positive subjects, one patient with AaIPI = 0, three with AaIPI ‫؍‬ 1, and two with AaIPI ‫؍‬ 2 relapsed. We conclude that FDG-PET is accurate in the prediction of relapse prior to HDT/SCT in patients with lymphoma. It provides additional information when compared with the AaIPI.
Introduction
When treated with high-dose chemo-or radiotherapy followed by autologous or allogeneic stem-cell transplantation (HDT/SCT), the prognosis of patients with relapsing and progressive Hodgkin's disease (HD), 1 as well as aggressive nonHodgkin's lymphoma (NHL) 2, 3 is generally better than after non-ablative salvage chemotherapy (ChT). With an intensified preparative regimen in chemosensitive disease 3-year PFS and OS were improved to 42% and 55%, respectively. 4 In chemoresistant disease the PFS and OS were 22% and 29%, respectively. In the same study, only disease status at SCT was a significant factor for both PFS and OS. In NHL, HDT/SCT in first remission has been found to be an independent factor for improved PFS. 5 A recent randomized trial showed a not sig- nificant trend for improved PFS for autologous SCT in first remission, but overall survival was not improved. 6 In relapsing HD a 2-year PFS rate of 42% after SCT was calculated. 7 Nuclear medicine imaging modalities are useful to predict the course of lymphoma in patients with residual abnormalities. 67 Gallium scanning is particularly useful with regard to viable tumour tissue in mediastinal masses, 8 but its sensitivity is lower than that of MRI. 9 Although CT scan can still be considered as the gold standard in staging lymphoma, positron emission tomography (PET) with [ 18 F] 2-fluoro-D-2-deoxyglucose (FDG) was found to be of high value in predicting a relapse in patients with residual masses after conventional ChT regimen and might even reveal better results than CT scans. 10, 11 So far, the relevance of FDG-PET in patients scheduled for HDT/SCT has not been defined. Thus, the present analysis was undertaken to evaluate a possible correlation between PET-findings before HDT/SCT and the course of the disease after HDT/SCT.
Patients and methods
The PET-patient database was reviewed for FDG-PET scans which were performed for staging of HD and NHL prior to SCT from February 1998 to April 2000. The patients included in our study had to undergo autologous or allogeneic HDT/SCT with a PET scan interposed between induction or reinduction therapy which might have been combined with irradiation and HDT/SCT. Only patients with PET studies performed within an interval of at least 3 weeks after the last ChT cycle or 12 weeks after the last irradiation and not more than 8 weeks prior to SCT were included.
Patients
Of 236 subjects with lymphoma who underwent a PET scan for various reasons, nine male and seven female patients with NHL (n = 10) and HD (n = 6) as shown in Table 1 were eligible for the study by the above-mentioned criteria. In the NHL group, age ranged from 25 to 56 years, mean 43.5 years. Patients with HD were 19 to 48 years old, mean 31.5 years. HDT/SCT was scheduled for a responsive relapse (RR) in six HD patients after achieving a second partial remission (PR) in five and a third PR in one of them. In NHL patients the indication for HDT/SCT was primarily refractory disease (RD) (n = 1), first PR (n = 5), second PR (n = 2), first complete remission (CR) with poor prognostic factors (n = 1), or second CR (n = 1). Lymphoma types in the NHL group were diffuse large B cell lymphoma (DLCBL) (n = 7), anaplastic large cell lymphoma of B cell type (n = 1), peripheral T cell lymphoma (n = 1), and mantle cell lymphoma (n = 1). The conditioning regimens administered for transplantation were BEAM for HD patients, CBV for DLCBL patients except the patient given an allogeneic SCT and TBI/Cy for all other patients. After HDT/SCT, follow-up was available for 4 to 28 months, median 13 months. Routine assessment of disease status consisted of bone marrow aspiration on days 28 and 100 after HDT/SCT, CT scan and ultrasound when clinically indicated 1, 3, 6, and 12 months after HDT/SCT. When evaluations were normal after transplantation, patients were assumed to be free of disease until a relapse was proven histologically (n = 2) or clinically (n = 6). All patients with bulky disease prior to HDT/SCT received local radiotherapy 2 to 3 months after HDT/SCT with a cumulative dose of 36 to 40 Gy to the bulk.
Positron emission tomography
All patients had at least one PET scan between induction ChT and before HDT/SCT. In addition, baseline PET scans before ChT were available in 11 patients and follow-up PETs after HDT/SCT in 13 patients.
Before the PET scan the patients fasted for at least 4 h. At tracer injection, all patients were normoglycemic with a blood glucose level Ͻ6 mmol/l. After intravenous injection of 370 MBq FDG the patients stayed in a relaxed supine position for 45 min. Due to this measure muscular tracer uptake was minimized. The scans were obtained on a dedicated full-ring PET scanner (GE Advance; GE Medical Systems, Milwaukee, USA) with an axial field-of-view of 15.2 cm, maximum resolution transaxially 3.8 mm, axially 4.0 mm. 12 The patients were scanned from head to thighs in the 2-D mode without attenuation correction. Over regions with focally increased uptake an additional attenuation-corrected scan using the built in 68 Ge sources was performed for calculation of the standardized uptake value (SUV) in 12 patients.
The scans were read visually. Areas of unequivocally pathoLeukemia logically increased uptake were reported as strongly positive (+++), positive (++), or weakly positive (+) by visual scoring. A homogenous pattern with normal FDG distribution and the absence of focally increased uptake was considered as negative (−). When a baseline scan before ChT was available for comparison, the response to therapy was assessed as follows. A change from a (+++) or (++) scan to a (+) scan was suggested as partial remission (PET-PR); a change to a completely negative scan as complete remission (PET-CR). All other cases were regarded as non-responders (PET-NR) or as progressive disease (PET-PD), the latter if lesion number, size, or intensity had increased. In two patients without a PET scan before ChT, a (+++) result was considered as PET-NR.
Conventional staging and follow-up procedures
Staging consisted of CT scans and bone marrow biopsy within 8 weeks before HDT/SCT. Twenty-eight days after HDT/SCT, all patients were re-evaluated with the same procedures. Ultrasound and MRI were facultative investigations. Gallium scans are not part of the staging routine in our institution. For assessment of the response to therapy, the standard criteria published by Cheson et al 13 were used.
Statistical analysis
Due to the relatively small number of patients, extensive statistical testing possibilities are limited. Testing for differences between the SUV at baseline and after induction ChT in the relapsing group and in the remission group was done by independent Student's t-test with a level of significance at P Ͻ 0.05. For assessment of a correlation between outcome, AaIPI and PET-results the exact Chi-square test was applied using StatXact 4 (Cytel Software, Cambridge, MA, USA); calculating the Kaplan-Meier plots was performed using the SPSS 10.0.7 software (SPSS, Chicago, IL, USA). 
Results
An overview of the PET results and the patients' history after SCT is given in Table 2 . Table 3 gives an overview over the disease localization, detailed PET-findings and the localization of the relapse after HDT/SCT. The progression-free survival was calculated as the time from day 0 of HDT/SCT to a relapse or to the end of the observation period.
PET-negative patients
PET was negative for viable lymphoma in five patients who therefore were quoted as PET-CR before HDT/SCT. All PET-CR patients stayed in clinical remission over the subsequent follow-up period of 11 to 28 months, median 17 months. In the case of three patients with PET-CR, a discrepant clinical stage with PR was found. One patient with NHL (FE) in the lumbar spine had a doubtful MRI after induction ChT and was therefore considered as PR. Of the two other patients, one had residual lesions on the CT scan before HDT/SCT (MM), the other had a positive bone marrow biopsy (AU).
PET-positive patients
In the PET-positive group, clinical remission status was first CR and second CR, respectively in one patient, PR in two patients, second PR (RR) in five patients, third PR in one patient, and refractory disease (RD) in one patient. In this group a follow-up was available from 4 to 21 months, median 8.5 months. One PET-NR patient with HD who was in PR by clinical staging, but a non-responder by PET died from HDT/SCT-related mortality due to septic multi-organ failure on day 20 after SCT and was excluded from further analysis. Of the other six PET-NR patients, five relapsed 1.5 to 7 months after HDT/SCT, median 6 months, and one patient never showed any response to HDT/SCT. One patient of this group died 4 months after HDT/SCT from chronic toxicity with a relapse diagnosed 2 weeks before. An example of a patient (JS2 , Tables 1 and 2 ) with persistent FDG uptake and without SUV decrease after induction therapy is shown in Figure 1a and b. Of the three PET-PR patients, one relapsed 6 months after SCT, while the other two patients Figure 2 shows an example of a patient (LM) with a weakly positive pre-HDT/SCT PET showing residual activity at the lymphoma site in the left lower leg. This focus corresponded to a nonspecific inflammatory process eventually confirmed by surgery as a fistula. The patient has stayed in CCR for 12 months.
In PET-positive patients, the disease-free survival after 1
Figure 2
(a) Peripheral T cell lymphoma in the left calf before ChT. (b) Before SCT the lesion showed reduction in size and intensity and was staged by PET as PR. After SCT an inflammatory process was confirmed without evidence of residual lymphoma. year was only 18% (two out of 11 patients). Four patients experiencing relapse after HDT/SCT are alive after salvage therapy. The overall mortality including early and late HDT/SCT-associated complications, after a positive PET was 45% (five out of 11 patients). The Kaplan-Meier curves show the marked differences in relapse-free survival (100% vs 18%) and overall survival (100% vs 55%) (Figure 3) . The association between the PET scan before HDT/SCT and the clinical outcome was significant (P Ͻ 0.01) and is shown in Table 4 .
With regard to prognosis, the PET stage before HDT/SCT was superior to the remission status based on conventional imaging as well. In the group with further clinical remission, before HDT/SCT there was only one patient in CR and one in PR, the remaining four patients had a responsive relapse (RR) while five were classified as PET-CR and two as PET-PR before HDT/SCT. From the relapsing patients, at HDT/SCT one was in CR, two in PR, four had an RR, and one RD in contrast to the PET-stage with only one PET-PR, but six PET-NR and one PET-PD.
PET after HDT/SCT
In seven out of eight relapsing patients, follow-up PETs were performed to confirm the clinical suspicion of the relapse and to show the extent of disease recurrence. All scans proved the relapse accurately and unequivocally. Interestingly, in patient JS2, a PET scan was negative on day 28 after HDT/SCT despite a FDG avid bulk before SCT and a PET-positive relapse half a year later (Figure 1c) . In six out of seven patients in clinical CR after HDT/SCT, subsequent PET scans were available showing no evidence of disease recurrence.
PET and international prognostic index
As all patients were younger than 60 years the age-adjusted international prognostic index (AaIPI) was applied in the NHL group. Two patients with negative PET, but AaIPI = 2 are still in remission, as well as one patient with AaIPI = 1, while in the seven PET-positive subjects one patient with AaIPI = 0, three patients with AaIPI = 1, and two patients with AaIPI = 2 relapsed. There was no significant correlation between PET or AaIPI vs clinical course after HDT/SCT (P Ͻ 0.13 for PET and P = 1 for the AaIPI, Table 5 ).
Standardized uptake value (SUV)
The SUVs at baseline of patients with a later relapse were higher than in patients in CCR (mean ± s.d. 17.4 ± 5.8 vs 9.9 ± 2.8, 95% CI: 0.2-14.8; P Ͻ 0.05). Patients remaining in remission had a more significant PET response to induction ChT as measured by the decrease of the SUV in comparison to those with a later relapse (SUV difference, 16.7 ± 6.2 vs 2.2 ± 1.7, 95% CI: 7.3-21.7; P Ͻ 0.001).
Figure 3
Kaplan-Meier blots of relapse-free and overall survival of patients with and without PET-response to induction ChT.
Table 4
Clinical outcome vs PET scan before HDT/SCT PET negative positive
Discussion
To our knowledge, the present study is the first to test a possible correlation between FDG-PET and the prognosis of patients with malignant lymphoma after HDT/SCT. Our data show that PET is an accurate predictor of relapse concerning this issue. All five patients with a negative PET before HDT/SCT are alive and free of disease after a follow-up of at least 11 months (mean 18 months), although only one had achieved a clinical CR, whereas the four others were classified as PR by conventional follow-up based mainly on CT. In the PET-positive group, eight out of 11 patients (67%) relapsed and three died of the disease (38%). Two patients died of transplantation-related complications 3 and 17 weeks, respectively, after HDT/SCT. Of the patients classified as PET-PR, two out of three are free of disease after HDT/SCT up to now. With regard to a relapse, their scans could be considered as false positive. However, in all three PET-PR patients the comparison to the baseline PET scan prior to ChT showed a decrease in the rating of the PET.
Leukemia
In agreement with the study of Romer et al 14 there was a significant decrease of the SUV after induction ChT only in patients who reached CCR after HDT/SCT. Although a significant difference in FDG uptake behavior before induction chemotherapy was noted, our results do not support the necessity of a baseline scan before (re-)induction ChT. It provided no additional information with regard to a later relapse in comparison to a single assessment of the pre-HDT/SCT scan.
In recent studies, PET had a higher prognostic value than CT in both HD and NHL. Jerusalem et al 11 analyzed 54 patients and found a positive predictive value of 100% for PET vs 42% for CT regarding a relapse in the case of a residual lesion. The relapse rate was only 10% in the case of a negative PET and a negative CT scan. Twenty-six percent of the patients with a residual mass on CT but negative PET relapsed, although in the case of 80% the relapse occurred outside the mass. The accuracy of PET in determining viability of residual lymphoma masses was also shown by Stumpe et al 15 who found a sensitivity/specificity of PET of 86%/96% for HD in 53 patients, and 89%/100% for NHL in 18 patients. Sensitivity/specificity for CT were 81%/41% for HD and 86%/67% for NHL. The difference in the specificity for HD was statistically significant showing the importance of the inclusion of PET particularly in the staging of HD. Another very recent study by Spaepen et al 16 was exclusively focused on the prognostic impact of FDG-PET after first-line ChT in NHL. Their results also confirmed the superiority of PET to CT.
Somewhat contradictory were the results in residual lymphoma masses by Maisey et al 17 with a PET sensitivity/specificity of only 50/69%. The markedly lower sensitivity in this study can be explained as follows. The study used an unusual scanner type which tolerates only 1/6 to 1/3 of the activity compared to full-ring scanners equipped with the typical bismuth-germanium-oxide (BGO) crystal detectors. Therefore, small lesions might have escaped detection. In addition, the scanner used in this study has a lower system resolution compared to a crystal detector ring. 18 As an alternative imaging method in determining tissue viability of residual masses 67 Gallium scintigraphy (GS) might be considered. It has been used for lymphoma imaging since 1969. 19 The results concerning the usefulness of GS in determining the prognosis of patients with lymphoma were equivocal in recent studies. [20] [21] [22] [23] The higher accuracy of FDG in HD, however, was confirmed by direct comparison of the two imaging modalities, 24 and in both HD and NHL a PETbased staging algorithm was found to be more cost-effective than conventional staging mainly based on GS, CT and MRI. 25 The question of prognosis is crucial for further treatment planning and follow-up strategies. Different factors influencing the course of patients with relapsing lymphoma are identified. Among them are age at diagnosis and length of initial remission. 26 The international prognostic index (IPI) summarizes different factors and has become an established parameter for risk stratification. 27 Recent data by Haioun et al 28 show that patients with aggressive NHL and higher risk factors in complete remission after induction ChT benefit from HDT with autologous SCT. In our study, however, the age-adjusted IPI (AaIPI) did not correlate with relapse or death (P = 1) while FDG-PET showed a slight trend (P Ͻ 0.13). Two patients with a negative PET, but an AaIPI = 2 are in CCR, while four patients who relapsed had an AaIPI р 1, but had been PETpositive before HDT/SCT. The result might of course be hampered by the small number of cases. Larger patient series will be needed for confirmation. Another recent study on HDT/SCT in low-grade lymphoma did not show differences in the OS for different IPIs either. 29 We found PET, however, promising for risk stratification and optimizing intensive therapeutic strategies. In case of an FDG-avid residual bulk after conventional ChT, allogeneic SCT could be an option. Since in our study only one patient had received allogeneic SCT (JP) and died 3 months later, almost all analyses are based on autologous SCT.
As a side issue, PET was also able to visualize the relapse after SCT, and also to document clinical remission. Remarkably, in one patient with PET-NR, PET was negative 4 weeks after HDT/SCT despite a relapse 6 months later. This might be due to stunning of the tumor cells after HDT/SCT. Therefore the usual recommendation to perform a PET scan for clinical purposes at the earliest 3 weeks to 1 month after ChT to avoid false-negative results, might be too soon in the case of highdose regimens. Furthermore, minimal residual disease probably present at this time is a potential pitfall for virtually every noninvasive imaging modality. The PCR-status after HDT/SCT has been found to be a prognostic factor at least in follicular lymphoma. 30 Perhaps recently introduced molecular methods with real-time PCR may be able to close the diagnostic gap from which PET obviously suffers. 31, 32 As a possible limitation to our study, the small number of patients must be mentioned. Therefore, HD and NHL were analyzed together. It remains an open question whether the high predictive value of PET in terms of the outcome of HDT/SCT is comparably true for the different lymphoma types in larger numbers of patients. In our series, however, HD and NHL did not differ in relapse rate when PET was positive before HDT/SCT.
In conclusion, patients scheduled for HDT/SCT showing high FDG uptake in the sites of lymphoma after induction ChT are at high risk for a relapse after HDT/SCT. On the other hand, a negative pre-SCT PET scan is associated with a favorable outcome. FDG-PET was able to identify patients at high risk, despite a low AaIPI. We conclude that FDG-PET is highly predictive in determining the prognosis after autologous HDT/SCT in high risk NHL, as well as in HD and may improve patient selection, as well as transplant strategy.
